Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $1,524,862.87 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 39,331 shares of the business’s stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $38.77, for a total transaction of $1,524,862.87. Following the sale, the chief executive officer owned 111,794 shares in the company, valued at $4,334,253.38. This represents a 26.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ KNSA opened at $38.93 on Friday. The company has a 50 day simple moving average of $36.42 and a 200-day simple moving average of $30.34. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of 973.49 and a beta of 0.16. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $39.79.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds have recently added to or reduced their stakes in the company. Rubric Capital Management LP increased its holdings in Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after buying an additional 526,567 shares during the last quarter. Vanguard Group Inc. grew its holdings in Kiniksa Pharmaceuticals International by 4.7% during the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock valued at $74,606,000 after purchasing an additional 151,604 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Kiniksa Pharmaceuticals International by 22.6% during the second quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock valued at $35,067,000 after purchasing an additional 233,668 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Kiniksa Pharmaceuticals International by 8.7% during the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. TD Cowen assumed coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a “buy” rating and a $60.00 price target for the company. Wedbush increased their price target on shares of Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the stock an “outperform” rating in a research report on Monday, October 13th. Wells Fargo & Company increased their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and an average price target of $46.86.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.